|Ms. Jodie Pope Morrison||Interim CEO & Director||41.74k||N/A||1975|
|Mr. Scott A. Holmes||CFO, Sr. VP & Treasurer||494.47k||N/A||1974|
|Ms. Christine A. Carberry||Sr. VP & COO||N/A||N/A||1961|
|Dr. John F. Neylan||Sr. VP & Chief Medical Officer||568.83k||N/A||1953|
|Mr. Tony Chambers||VP of Sales||N/A||N/A||N/A|
Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.
Keryx Biopharmaceuticals, Inc.’s ISS Governance QualityScore as of August 1, 2018 is 5. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 5; Compensation: 8.